TKT to Present at SG Cowen Securities' 25th Annual HealthCare Conference
March 09 2005 - 2:21PM
PR Newswire (US)
TKT to Present at SG Cowen Securities' 25th Annual HealthCare
Conference CAMBRIDGE, Mass., March 9 /PRNewswire-FirstCall/ --
Transkaryotic Therapies, Inc. (NASDAQ:TKTX) today announced that
the company will present at SG Cowen Securities' 25th Annual
Healthcare Conference being held in Boston, Massachusetts, March
14-17, 2005. Michael J. Astrue, President and Chief Executive
Officer will present an overview and update of TKT's business
activities and product pipeline at 11:20 a.m. - 12:00 p.m. Eastern
Time on Wednesday, March 16, 2005. A live audio webcast of this
presentation will be available at http://www.tktx.com/ on TKT's
Investor Information website under the Events category. A replay
will be available for approximately 30 days after the webcast.
About TKT Transkaryotic Therapies, Inc. is a biopharmaceutical
company primarily focused on researching, developing and
commercializing treatments for rare diseases caused by protein
deficiencies. Within this focus, the company markets Replagal(TM),
an enzyme replacement therapy for Fabry disease, and is developing
treatments for Hunter syndrome and Gaucher disease. In addition to
its focus on rare diseases, TKT intends to commercialize
Dynepo(TM), its Gene- Activated(R) erythropoietin product for
anemia related to kidney disease, in the European Union. TKT was
founded in 1988 and is headquartered in Cambridge, Massachusetts,
with additional operations in Europe, Canada and South America.
Additional information about TKT is available on the company's
website at http://www.tktx.com/. Gene-Activated(R) is a registered
trademark and Replagal(TM) is a trademark of Transkaryotic
Therapies, Inc. Dynepo(TM) is a trademark of Sanofi-Aventis SA.
Contact: Daniella M. Lutz Corporate Communications Manager (617)
349-0205 http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
http://photoarchive.ap.org/ DATASOURCE: Transkaryotic Therapies,
Inc. CONTACT: Daniella M. Lutz, Corporate Communications Manager of
Transkaryotic Therapies, Inc., +1-617-349-0205 Web site:
http://www.tktx.com/ Company News On-Call:
http://www.prnewswire.com/comp/120657.html
Copyright
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Jul 2023 to Jul 2024